Article Text
PDFElectronic pages
Clopidogrel induced urticarial rash in a patient with left main stem percutaneous coronary intervention: management issues
Abstract
Clopidogrel, an ideal treatment for prevention of subacute stent thrombosis, may not be feasible to use in every patient. Ticlopidine (plus aspirin) is a very good alternative, although the risks of life threatening neutropenia should mandate regular monitoring of blood counts. It is proposed that patients undergoing angioplasty and stenting should carry a warning card in an effort to make the public and general practitioners aware that antiplatelet treatment after angioplasty plays an important part in ensuring successful outcome.
- antithrombotic regimen
- clopidogrel allergy
- left main stem angioplasty
- ticlopidine
- ATLAST, antiplatelet therapy alone versus lovenox plus antiplatelet therapy in patients at increased risk of stent thrombosis
- CLASSICS, clopidogrel aspirin stent international cooperative study
- ENTICES, enoxaparin and ticlopidine after elective stenting
- FANTASTIC, full anticoagulation versus aspirin and ticlopidine trial
- MATTIS, multicenter aspirin and ticlopidine trial after intracoronary stenting
- STARS, stent antithrombotic regimen study
Statistics from Altmetric.com
- ATLAST, antiplatelet therapy alone versus lovenox plus antiplatelet therapy in patients at increased risk of stent thrombosis
- CLASSICS, clopidogrel aspirin stent international cooperative study
- ENTICES, enoxaparin and ticlopidine after elective stenting
- FANTASTIC, full anticoagulation versus aspirin and ticlopidine trial
- MATTIS, multicenter aspirin and ticlopidine trial after intracoronary stenting
- STARS, stent antithrombotic regimen study